Iwahashi Chiharu, Tachibana Kuniko, Oga Tomoyuki, Kondo Chiori, Kuniyoshi Kazuki, Kusaka Shunji
Department of Ophthalmology, Kindai University Faculty of Medicine, Osaka, Japan.
Department of Ophthalmology, Kindai University Faculty of Medicine, Osaka, Japan.
Ophthalmol Retina. 2021 Nov;5(11):1139-1145. doi: 10.1016/j.oret.2021.01.008. Epub 2021 Jan 20.
To determine the incidence and factors associated with lens opacity after lens-sparing vitrectomy (LSV) for retinopathy of prematurity (ROP).
Retrospective, comparative case series.
Among the 141 eyes of 94 patients who underwent LSV for ROP between 2006 and 2019, 108 eyes of 71 patients with a minimum follow-up of 12 months after LSV were investigated.
Data were collected from patients' charts, including gender, gestational age at birth, birth weight, stage of ROP, postmenstrual age (PMA) at LSV, surgical procedure, preoperative injection of anti-vascular endothelial growth factor (VEGF) agents, subsequent retinal surgeries, and lensectomy during follow-up.
Lens status at last visit, incidence and timing of lensectomy, and risk factors for lens opacity requiring lensectomy.
Stages of ROP at LSV were 4A, 4B, and 5 in 92 eyes, 13 eyes, and 3 eyes, respectively. The median PMA at LSV was 40.6 weeks. Thirty-two eyes received anti-VEGF therapy before LSV. Lens opacity was found in 17 eyes (15.7%), of which 10 eyes (9.3%) underwent lensectomy. The period between LSV and lensectomy ranged from 21 days to 131.9 months (median, 21.1 months). Eleven other eyes (10.2%) underwent lensectomy as part of a reoperation for worsening of ROP. A total of 80 eyes (74.1%) preserved clear lenses at the latest follow-up examination after surgery (median, 6.8 years; range, 1-14 years). The Kaplan-Meier estimate showed that the proportion of patients with phakia at 5 and 10 years was 92.4% and 89.0%, respectively. Multivariate Cox regression analysis revealed that eyes with the use of tamponade at LSV (P = 0.005; odds ratio [OR], 25.68; 95% confidence interval [CI], 4.187-157.5) and young PMA at LSV (P = 0.033; OR, 1.047; 95% CI, 1.012-1.099) were associated significantly with lens opacity requiring lensectomy. However, anti-VEGF therapy was not associated with lens opacity requiring lensectomy.
Nearly 10% of eyes required lensectomy because of lens opacity after LSV for ROP. The development of lens opacity requiring lensectomy seems to be associated with the use of tamponade and young PMA at LSV.
确定早产儿视网膜病变(ROP)行晶状体保留玻璃体切除术(LSV)后晶状体混浊的发生率及相关因素。
回顾性、对比病例系列研究。
2006年至2019年间,94例接受ROP的LSV手术的患者共141只眼,其中71例患者的108只眼在LSV术后至少随访12个月并纳入研究。
从患者病历中收集数据,包括性别、出生时的胎龄、出生体重、ROP分期、LSV时的月经后年龄(PMA)、手术方式、术前抗血管内皮生长因子(VEGF)药物注射、后续视网膜手术以及随访期间的晶状体切除术。
末次随访时的晶状体状态、晶状体切除术的发生率和时间,以及需要晶状体切除术的晶状体混浊的危险因素。
LSV时ROP分期为4A期、4B期和5期的分别有92只眼、13只眼和3只眼。LSV时的PMA中位数为40.6周。32只眼在LSV前接受了抗VEGF治疗。17只眼(15.7%)发现晶状体混浊,其中10只眼(9.3%)接受了晶状体切除术。LSV至晶状体切除术的时间间隔为21天至131.9个月(中位数为21.1个月)。另外11只眼(10.2%)因ROP病情恶化作为再次手术的一部分接受了晶状体切除术。术后最新一次随访检查时,共有80只眼(74.1%)晶状体保持透明(中位数为6.8年;范围为1 - 14年)。Kaplan-Meier估计显示,5年和10年时晶状体未摘除的患者比例分别为92.4%和89.0%。多因素Cox回归分析显示,LSV时使用填塞物的眼(P = 0.005;比值比[OR]为25.68;95%置信区间[CI]为4.187 - 157.5)和LSV时PMA较小的眼(P = 0.033;OR为1.047;95% CI为1.012 - 1.099)与需要晶状体切除术的晶状体混浊显著相关。然而,抗VEGF治疗与需要晶状体切除术的晶状体混浊无关。
ROP行LSV术后,近10%的眼因晶状体混浊需要行晶状体切除术。需要晶状体切除术的晶状体混浊的发生似乎与LSV时使用填塞物和PMA较小有关。